

## Who can administer

May be administered by registered competent doctor or nurse/midwife

## Important information

### Unlicensed product

- Supplied on compassionate use by renal specialists
- Patient must be informed of unlicensed status before it is administered to them

## Available preparations

0.075mg per 1.5mL vial (0.05mg/ml)

A volume of 1.3mL is extractable from each vial

## Methods of intravenous administration

### Intravenous bolus injection

- Do not mix or dilute the injection solution prior to administration
- The drug is removed by the dialyser membrane and must be administered after blood is no longer circulating through the dialyser
- Administer by intravenous bolus injection into the venous line of the dialysis circuit at the end of each HD session
  - The dose may be given either during or after rinse back of the dialysis circuit.
  - If the dose is given **after rinse back**, administer it into the venous line followed by at least 10 mL of Sodium chloride 0.9% flush
  - If the dose is given **during rinse back**, no additional Sodium chloride 0.9% is needed to flush the line
  - The dose must be administered within 60 minutes of the completion of the syringe preparation. Discard any unused product

## Dose in adults

### Moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis

- The recommended dose is 0.5 mcg/kg at the end of each HD session (see next point re weight to use)
- The dose/kg is determined by patient's **target dry body weight in kilograms** See Table 1.
- If a regularly scheduled HD treatment is missed, resume administration of the drug at the end of the next HD treatment

**Table 1: Injection volume based on Target Dry Weight**

| Target Dry Body Weight Range (kg) | Injection volume (mL) |
|-----------------------------------|-----------------------|
| 36-44                             | 0.4                   |
| 45-54                             | 0.5                   |
| 55-64                             | 0.6                   |
| 65-74                             | 0.7                   |
| 75-84                             | 0.8                   |
| 85-94                             | 0.9                   |
| 95-104                            | 1                     |
| 105-114                           | 1.1                   |
| 115-124                           | 1.2                   |
| 125-134                           | 1.3                   |
| 135-144                           | 1.4                   |
| 145-154                           | 1.5                   |
| 155-164                           | 1.6                   |
| 165-174                           | 1.7                   |
| 175-184                           | 1.8                   |
| 185-194                           | 1.9                   |
| 195-204                           | 2                     |

\* Total Injection Volume (mL) = Patient Target Dry Body Weight (kg) x 0.01, rounded to the nearest tenth (0.1 mL).

Use this formula for patient target dry body weight outside of the ranges in above table

Â

## Further information

- Difelikefalin has not been studied in patients on peritoneal dialysis and is not recommended for use in this population

## Storage

Store below 25°C

## References

Korsuva SPC 08/2021

## Therapeutic classification

Kappa opioid receptor agonist